Status:

COMPLETED

Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss

Lead Sponsor:

Case Comprehensive Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Cachexia

Pancreatic Cancer

Eligibility:

All Genders

18+ years

Brief Summary

RATIONALE: Learning about biological markers in patients with pancreatic cancer and cachexia may help doctors predict patient outcome and may help the study of cancer in the future. PURPOSE: This lab...

Detailed Description

OBJECTIVES: * Compare levels of caspase-3 and phosphorylated Akt (pAkt) in the rectus abdominous muscle of patients with pancreatic cancer who are experiencing cachexia and are undergoing surgery for...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Meets 1 of the following criteria:
  • Diagnosis or suspicion of pancreatic cancer
  • Any stage disease allowed
  • At least 5% weight loss within the past 6 months
  • Scheduled to undergo exploratory surgery
  • Scheduled to undergo exploratory surgery for suspected nonmalignant condition
  • No weight loss OR weight loss due to specific reason (e.g., bowel obstruction, infection, or nausea/vomiting)
  • No cancer diagnosis other than primary pancreatic carcinoma
  • PATIENT CHARACTERISTICS:
  • ECOG performance status 0-3
  • Life expectancy ≥ 12 weeks
  • No pacemakers or implanted defibrillators
  • PRIOR CONCURRENT THERAPY:
  • Prior or concurrent chemotherapy and radiotherapy allowed
  • Prior or concurrent biological therapy and surgery allowed
  • At least 4 weeks since prior corticosteroids or anabolic steroids
  • Other concurrent anticancer therapy allowed
  • No concurrent corticosteroids or anabolic steroids, thalidomide, eicosapentaenoic acid (EPA), or Juven for weight loss
  • Concurrent steroids (i.e., antiemetics) associated with chemotherapy allowed
  • No concurrent nutritional supplements with EPA

Exclusion

    Key Trial Info

    Start Date :

    June 1 2005

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2008

    Estimated Enrollment :

    44 Patients enrolled

    Trial Details

    Trial ID

    NCT00899158

    Start Date

    June 1 2005

    End Date

    December 1 2008

    Last Update

    September 30 2015

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

    Cleveland, Ohio, United States, 44106

    Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss | DecenTrialz